Panacur 2.5% Oral Suspension

País: Reino Unido

Idioma: inglés

Fuente: VMD (Veterinary Medicines Directorate)

Ingredientes activos:

Fenbendazole

Disponible desde:

Intervet UK Ltd

Código ATC:

QP52AC13

Designación común internacional (DCI):

Fenbendazole

Estado de Autorización:

Expired

Ficha técnica

Revised: 08 June 2010
AN: 00344/2010
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT FOLLOWED BY
THE STRENGTH AND THE PHARMACEUTICAL FORM
Panacur 2.5% Oral suspension
2.
NAME AND PROPORTION OF EACH ACTIVE SUBSTANCE, AND OF ANY
EXCIPIENT, IF KNOWLEDGE OF THE EXCIPIENT IS NEEDED FOR
SAFETY REASONS
Active substance
%w/v
Fenbendazole
2.500
Other substances
Sodium methyl hydroxybenzoate
0.200
Sodium propyl hydroxybenzoate
0.0216
Benzyl alcohol
0.4835
For full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
White, practically odourless oral suspension
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle and sheep
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
A broad spectrum anthelmintic for the treatment of sheep and cattle
infected
with mature and developing immature forms of nematodes of the gastro-
intestinal and respiratory tracts.
Cattle: For the treatment of cattle infected with:
Ostertagia spp.
Cooperia spp.
Trichostrongylus spp.
Nematodirus spp.
Haemonchus spp.
Oesophagostomum spp.
Bunostomum spp.
Strongyloides spp.
Trichuris spp.
_Dictyocaulus viviparus_
Panacur is usually effective against inhibited larvae of Ostertagia
spp. and
against Moniezia spp. of tapeworm.
Page 1 of 6
Revised: 08 June 2010
AN: 00344/2010
Sheep: For the treatment of sheep infected with benzimidazole
susceptible:
Ostertagia spp.
Haemonchus spp.
Trichostrongylus spp.
Nematodirus spp.
Cooperia spp.
Oesophagostomum spp.
Chabertia spp.
Bunostomum spp.
Strongyloides spp.
_Dictyocaulus filaria_
Panacur is usually effective against Moniezia spp. of tapeworm and may
have
useful but variable efficacy against Trichuris spp.
4.3
CONTRA-INDICATIONS
None
4.4
SPECIAL WARNING FOR EACH TARGET SPECIES
Care should be taken to avoid the following practices because they
increase
the risk of development of resistance and could ultimately result in
ineffective
therapy:

Too frequent and repeated use of anthelmintics from the same class,
over an extended period of time.

Under dosing, which may be due to u